Cargando…
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
The purpose of making a “biobetter” biologic is to improve on the salient characteristics of a known biologic for which there is, minimally, clinical proof of concept or, maximally, marketed product data. There already are several examples in which second-generation or biobetter biologics have been...
Autor principal: | Strohl, William R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562006/ https://www.ncbi.nlm.nih.gov/pubmed/26177629 http://dx.doi.org/10.1007/s40259-015-0133-6 |
Ejemplares similares
-
Future of anti-VEGF: biosimilars and biobetters
por: Kapur, Monika, et al.
Publicado: (2022) -
Biobetters From an Integrated Computational/Experimental Approach
por: Kuyucak, Serdar, et al.
Publicado: (2017) -
From Biologics to Biosimilars and Biobetters – Democratization of High-end Therapeutics
por: Honavar, Santosh G
Publicado: (2021) -
Biosimilar, biobetter and next generation therapeutic antibodies
Publicado: (2011) -
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters
por: Kim, HoUng, et al.
Publicado: (2021)